文獻：Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA

文獻鏈接：https://xueshu.baidu.com/usercenter/paper/show?paperid=13620650816s00y0k60q02j0k0742988&site=xueshu_se

作者：G Tian，R Pan，B Zhang，M Qu，J Wu

摘要：

Combination therapy based on nano-sized drug delivery system has been developed as a promising strategy by combining two or more anti-tumor mechanisms. Here, we prepared liver-targeted nanoparticles (GH-DPP) composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-polyetherimide (DSPE-PEG-PEI) with Glycyrrhetinic acid-modified hyaluronic acid (GA-HA) for co-delivery of doxorubicin (DOX) and Bcl-2 siRNA. Particles size, zeta potential and morphology were determined for the drug-loaded GH-DPP nanoparticles (siRNA/DOX/GH-DPP). Cellular uptake and in vitro cytotoxicity were analyzed against HepG2 cells. In vivo bio-distribution and anti-tumor therapeutic effects of siRNA/DOX/GH-DPP were evaluated in H22-bearing mice. The results showed that siRNA/DOX/GH-DPP nanoparticles were nearly spherical and showed dose-dependent cytotoxicity against HepG2 cells. 

基于納米級藥物遞送系統的聯合治療已被開發為一種有前景的策略，通過結合兩種或多種抗腫瘤機制。在這里，我們制備了由1,2-二硬脂酰基-sn-甘油-3-磷酸乙醇胺-聚乙二醇聚醚酰亞胺（DSPE-PEG-PEI）和甘草次酸修飾的透明質酸（GA-HA）組成的肝靶向納米顆粒（GH-DPP），用于阿霉素（DOX）和Bcl-2 siRNA的共遞送。測定了載藥GH-DPP納米顆粒（siRNA/DOX/GH-DPP）的粒徑、ζ電位和形態。對HepG2細胞的細胞攝取和體外細胞毒性進行了分析。在攜帶H22的小鼠體內評估siRNA/DOX/GH-DCP的體內生物分布和抗腫瘤治療效果。結果表明，siRNA/DOX/GH-DCP納米顆粒呈近球形，對HepG2細胞具有劑量依賴性細胞毒性。

相關推薦：

DSPE-PEG-Cy7

DSPE-PEG-cRGD

DPPE-PEG-cRGD

DMPE-PEG-cRGD

DOPE-PEG-cRGD

DPPE-PEG-RGD

DMPE-PEG-RGD

版權聲明：

本平臺根據相關科技期刊文獻、教材以及網站編譯整理的內容，僅用于對相關科學作品的介紹、評論以及課堂教學或科學研究。如有侵權，請聯系我們刪除。